Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis

NCT05784246 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05784246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05784246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
November 22, 2023
Completion date
May 1, 2026
Enrollment
63 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis